Quantitative intratumoural microdistribution and kinetics of 131I-huA33 antibody in patients with colorectal carcinoma

EJNMMI Research

Volumn 4, Issue 1, 2014, Pages 1-10

  Ciprotti, Marika ^a   Chong, Geoffrey ^a   Gan, Hui K ^a   Chan, Anthony ^a   Murone, Carmel ^a,b   MacGregor, Duncan ^b   Lee, Fook Thean ^a   Johns, Terrance G ^c   Heath, Joan K ^a,d   Ernst, Matthias ^a,d   Burgess, Antony W ^d   Scott, Andrew M ^a,b  

^a OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^b AUSTIN HEALTH   (Australia)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Colon cancer; Immunotherapy; Microdistribution; Monoclonal antibody

Indexed keywords

IODINE 131; IODINE 131 HUMANIZED A33 ANTIBODY; RECOMBINANT ANTIBODY; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; BILIRUBIN BLOOD LEVEL; CELL VIABILITY; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CREATININE BLOOD LEVEL; DRUG DISTRIBUTION; ELECTIVE SURGERY; FEMALE; GAMMA COUNTER; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTHROMBIN TIME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOCYTE COUNT; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 84901866264     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/s13550-014-0022-x     Document Type: Article

References (41)

1. Divgi CR, Bander NH, Scott AM, O’Donoghue JA, Sgouros G, Welt S, Finn RD, Morrissey F, Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC, Larson SM, Old LJ: Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.Clin Cancer Res 1998, 4:2729–2739.
2. Scott AM, Wolchok JD, Old LJ: Antibody therapy of cancer.Nat Rev Cancer 2012, 12:278–287.
3. Boxer GM, Abassi AM, Pedley RB, Begent RH: Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA)–implications for targeted therapy.Br J Cancer 1994, 69:307–314.
4. Boxer GM, Begent RH, Kelly AM, Southall PJ, Blair SB, Theodorou NA, Dawson PM, Ledermann JA: Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma–implications for radioimmunotherapy.Br J Cancer 1992, 65:825–831.
5. Chung JK, Jang JJ, Lee DS, Lee MC, Koh CS: Tumor concentration and distribution of carcinoembryonic antigen measured by in vitro quantitative autoradiography.J Nucl Med 1994, 35:1499–1505.
6. Flynn AA, Boxer GM, Begent RH, Pedley RB: Relationship between tumour morphology, antigen and antibody distribution measured by fusion of digital phosphor and photographic images.Cancer Immunol Immunother 2001, 50:77–81.
7. Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.Cancer Res 1990, 50:819.
8. Murray JL, Rosenblum MG, Zhang HZ, Podoloff DA, Kasi LP, Curley SA, Chan JC, Roh M, Hohn DC, Brewer H: Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab’)2 in colorectal cancer patients.Cancer 1994, 73:850–857.
9. Steffens MG, Oosterwijk E, Zegwaart-Hagemeier NE, van’t Hof MA, Debruyne FM, Corstens FH, Boerman OC: Immunohistochemical analysis of intratumoral heterogeneity of [131I]cG250 antibody uptake in primary renal cell carcinomas.Br J Cancer 1998, 78:1208–1213.
10. Taddei-Peters WC, Haspel MV, Vente P, Murray JL, Cleary KR, Levin B, Paris EM, Pomato N, Murray JH, Weidman D: Quantitation of human tumor-reactive monoclonal antibody 16.88 in the circulation and localization of 16.88 in colorectal metastatic tumor tissue using murine antiidiotypic antibodies.Cancer Res 1992, 52:2603–2609.
11. Brown RS, Kaminski MS, Fisher SJ, Chang AE, Wahl RL: Intratumoral microdistribution of [131I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy.Nucl Med Biol 1997, 24:657–663.
12. Catimel B, Ritter G, Welt S, Old LJ, Cohen L, Nerrie MA, White SJ, Heath JK, Demediuk B, Domagala T, Lee FT, Scott AM, Tu GF, Ji H, Moritz RL, Simpson RJ, Burgess AW, Nice EC: Purification and characterization of a novel restricted antigen expressed by normal and transformed human colonic epithelium.J Biol Chem 1996, 271:25664–25670.
13. Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, Tu GF, Ji H, Whitehead RH, Groenen LC, Scott AM, Ritter G, Cohen L, Welt S, Old LJ, Nice EC, Burgess AW: The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily.Proc Natl Acad Sci U S A 1997, 94:469–474.
14. Ritter G, Cohen LS, Nice EC, Catimel B, Burgess AW, Moritz RL, Ji H, Heath JK, White SJ, Welt S, Old LJ, Simpson RJ: Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium.Biochem Biophys Res Commun 1997, 236:682–686.
15. Garinchesa P, Sakamoto J, Welt S, Real F, Rettig W, Old L: Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy.Int J Oncol 1996, 9:465–471.
16. Van den Eynde BJ, Scott AM: Tumor antigens. In Encyclopedia of Immunology (Second Edition). Edited by Peter JD. Oxford: Elsevier; 1998:2424–2431.
17. Scott AM, Welt S: Antibody-based immunological therapies.Curr Opin Immunol 1997, 9:717–722.
18. Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Germain JS, Richards EC, Larson SM, Oettgen HF: Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.J Clin Oncol 1994, 12:1561–1571.
19. Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, Germain JS, Richards EC, Larson SM, Old LJ: Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer.J Clin Oncol 1996, 14:1787–1797.
20. 131I-huA33 in patients with advanced colorectal carcinoma.Clin Cancer Res 2005, 11:4818–4826.
21. King DJ, Antoniw P, Owens RJ, Adair JR, Haines AM, Farnsworth AP, Finney H, Lawson AD, Lyons A, Baker TS: Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy.Br J Cancer 1995, 72:1364–1372.
22. 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.J Nucl Med 2011, 52:1878–1885.
23. Scott AM, Lee F-T, Jones R, Hopkins W, MacGregor D, Cebon JS, Hannah A, Chong GUP, Papenfuss A, Rigopoulos A, Sturrock S, Murphy R, Wirth V, Murone C, Smyth FE, Knight S, Welt S, Ritter G, Richards E, Nice EC, Burgess AW, Old LJ: A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake.Clin Cancer Res 2005, 11:4810–4817.
24. Welt S, Ritter G, Williams C, Cohen LS, John M, Jungbluth A, Richards EA, Old LJ, Kemeny NE: Phase I study of anticolon cancer humanized antibody A33.Clin Cancer Res 2003, 9:1338–1346.
25. Welt S, Ritter G, Williams C, Cohen LS, Jungbluth A, Richards EA, Old LJ, Kemeny NE: Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer.Clin Cancer Res 2003, 9:1347–1353.
26. Lee FT, Hall C, Rigopoulos A, Zweit J, Pathmaraj K, O’Keefe GJ, Smyth FE, Welt S, Old LJ, Scott AM: Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody.J Nucl Med 2001, 42:764–769.
27. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJP, Weiner LM, Marks JD, Adams GP: Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors.Cancer Res 2011, 71:2250–2259.
28. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM: High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.Cancer Res 2001, 61:4750–4755.
29. Fujimori K, Covell DG, Fletcher JE, Weinstein JN: Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab’)2, and Fab in tumors.Cancer Res 1989, 49:5656–5663.
30. Fujimori K, Covell DG, Fletcher JE, Weinstein JN: A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.J Nucl Med 1990, 31:1191–1198.
31. Rhoden JJ, Wittrup KD: Dose dependence of intratumoral perivascular distribution of monoclonal antibodies.J Pharm Sci 2012, 101:860–867.
32. Thurber GM, Wittrup KD: Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids.Cancer Res 2008, 68:3334–3341.
33. Ackerman ME, Pawlowski D, Wittrup KD: Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids.Mol Cancer Ther 2008, 7:2233–2240.
34. Maeda H: The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.Adv Enzyme Regul 2001, 41:189–207.
35. Maeda H, Bharate GY, Daruwalla J: Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.Eur J Pharm Biopharm 2009, 71:409–419.
36. Ackerman ME, Chalouni C, Schmidt MM, Raman VV, Ritter G, Old LJ, Mellman I, Wittrup KD: A33 antigen displays persistent surface expression.Cancer Immunol Immunother 2008, 57:1017–1027.
37. Sung C, Shockley TR, Morrison PF, Dvorak HF, Yarmush ML, Dedrick RL: Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors.Cancer Res 1992, 52:377–384.
38. Thurber GM, Zajic SC, Wittrup KD: Theoretic criteria for antibody penetration into solid tumors and micrometastases.J Nucl Med 2007, 48:995–999.
39. Welt S, Divgi CR, Real FX, Yeh SD, Garin-Chesa P, Finstad CL, Sakamoto J, Cohen A, Sigurdson ER, Kemeny N: Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33.J Clin Oncol 1990, 8:1894–1906.
40. Arjaans M, Oosting SF, Schroder CP, de Vries EGE: Bevacizumab-induced vessel normalization hampers tumor uptake of antibodies–response.Cancer Res 2013, 73:7147–7148.
41. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.J Nucl Med 2010, 51:1707–1715.